The rise of chronic diseases is shaping health policy priorities worldwide. As the population ages, these conditions affect increasing portions of society and are more difficult to manage, causing suffering in patients and their f...
ver más
RYC2020-029099-I
Bioengineering Molecular Imaging Tools for Precision Medicin...
324K€
Cerrado
TED2021-132296A-C53
BIOFISICA COMPUTACIONAL PARA LA DIGITALIZACION DE LEUCEMIA I...
133K€
Cerrado
LifeTime
Revolutionizing Healthcare by Tracking and Understanding Hum...
1M€
Cerrado
FJC2021-046986-I
Evaluation of Novel Imaging Technologies combined with Artif...
65K€
Cerrado
RYC2021-033127-I
Machine Learning methods for translational biomedicine
236K€
Cerrado
iLoF
iLoF: AI-augmented photonics to identify and quantify diseas...
4M€
Cerrado
Últimas noticias
27-11-2024:
Videojuegos y creaci...
Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital
27-11-2024:
DGIPYME
En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones
Descripción del proyecto
The rise of chronic diseases is shaping health policy priorities worldwide. As the population ages, these conditions affect increasing portions of society and are more difficult to manage, causing suffering in patients and their families for many years. Such increasing prevalence is a threat to the sustainability of healthcare systems. Thus, an increasing focus has been put on disease prevention and awareness, as well as on precision medicine. This project will create a new Centre of Excellence, NOVA Institute for Medical Systems Biology (NIMSB), which will use the most advanced cell analytics and experimental in vitro systems, combined with computational approaches to understand and fight chronic diseases. The core of the project will be the integration of multi-omics data from single cells from patient biopsies and derived organoids, bioinformatics and artificial intelligence, cell and molecular biology, and relevant animal model studies, to develop quantitative models that can inform on mechanisms of disease progression. Researchers and clinicians will collaborate to use this knowledge to implement novel precision medicine solutions, aiming to intercept diseases before symptoms develop, and also by improving diagnosis, disease course prediction and response to treatment. NIMSB will contribute to clinical practice improvement not only with technology but also by training the next generation of researchers and medical doctors in precision interceptive medicine and digital-transformation technologies. NOVA Medical School of NOVA University is in a unique position to coordinate the project due to its current drive for restructuring, established reputation as a top Medical School in Portugal, and research focus on chronic diseases. The Max Delbrück Center for Molecular Medicine is the best possible advanced partner, as it is a world leader in this research topic and has recently created the Berlin Institute for Medical Systems Biology, which is a model for NIMSB.
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.